Navigation Links
Karo Bio Announces Sucessfule Phase II Results of KB2115

HUDDINGE, Sweden,11-Jun-2007 / Karo Bio (STO:KARO) successful KB2115 Phase II study meets primary objectives. The 12 week proof of concept phase II study with KB2115 in patients with dyslipidemia has been successfully completed. KB2115 is efficacious in LDL lowering and safe with respect to a broad range of parameters reflecting effects on heart, bone, muscle and thyroid function.

The thyroid hormone receptor (TR) is a key regulator of metabolic pathways and holds the promise of a new target for the treatment of dyslipidemia. KB2115 is an innovative and first in class liver selective agonist for the TR. Unlike the natural thyroid hormones, KB2115 is a liver selective TR agonist that can induce pharmacological effects in the liver, while a normal thyroid state is preserved in the rest of the body.

The completed 12 week, placebo controlled, double blind, randomised, clinical phase II study in 99 patients with high cholesterol levels was designed to explore whether a clinically relevant LDL-cholesterol lowering effect can be achieved without affecting the heart, bone, muscle and thyroid function.

The study demonstrated that a pronounced and clinically relevant lowering of LDL cholesterol can be obtained while preserving the thyroid homeostasis outside the liver and biomarkers for heart, bone, muscle and other organs were kept at normal levels. The mild increase in liver enzymes that was picked up in the previous 2-week phase I trial, was observed in this study as well, however, it seems to be a transient and benign effect. In addition to the positive result regarding efficacy and safety it was also shown that the enteric coating of KB2115 was effective in protecting the compound from chemical modification in the stomach.Thereby, a safety concern for longer exposure in man is removed.

The specific results from the KB2115 phase II study will be presented at upcoming international conferences dur
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Karo Bio Announces Sucessfule Phase Results
(Date:10/31/2014)... 31, 2014  Grammy Award-winner Bruce Hornsby ... of philanthropists, athletes, actors, and musicians during the 10 ... 19 at the Mandarin Oriental Hotel in ... will honor six individuals who embody the values of ... bestow its highest honor, the Spirit of an Active ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... 2014 Imago BioSciences, Inc., a biotech ... million Series A financing led by Clarus Ventures ... team of accomplished investment and operating professionals dedicated ... round include Frazier Healthcare, Amgen Ventures, and Merck ... and Frazier Healthcare will join the company,s board ...
Breaking Medicine Technology:10th Anniversary Orthopaedic Foundation Gala Set For Success 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2
... Boston Scientific Corporation (NYSE: BSX ) today announced ... Johnson & Johnson, including the Palmaz-NIR suit. All ... arena. In connection with the settlement, Boston Scientific ... & Johnson. The settlement payment is within Boston ...
... MUMBAI, India, Sept. 29 Pharmaceutical Major, Lupin Ltd. announced ... 43 mg and 130 mg). Lupin acquired the product ... of the U.S. Bankruptcy Court. Antara recorded net sales ... 2008). Lupin paid $ 38.61 million for the product ...
Cached Medicine Technology:Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 2Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 3Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 4Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, ... organ transplantation is nothing new. The first kidney transplant ... in 1963 and the first human heart transplant in 1967. ... patient,s entire face. One major organ still eludes the ... team of U.S. scientists has its way, that dream may ...
(Date:10/31/2014)... News) -- Each year, people across the United States ... relatives and friends, which costs $522 billion, according to ... price tag on the time and wages that caregivers ... need assistance in daily activities. The study authors said ... interest in workplace flexibility policies. "Our findings provide ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... the DFG Research Center for Regenerative Therapies Dresden - ... for the first time the in vitro growth of ... mouse embryonic stem cells. Correct spatial organization of motor ... was observed., This study has been published online by ... on 30.10.2014 ., For many years Elly Tanaka and ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Graphics, coding, ... are synonymous with the craft of web design and ... website. Yet a simpler solution to create a website ... pictures, videos, contact information, customer reviews and Facebook posts ... "It is the next evolution of how a ...
Breaking Medicine News(10 mins):Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Facebook Websites In Thirty-Seconds 2
... who performed a small study on stroke patients conclude that ... cognitive abilities//. ,The study was conducted at Sacred Heart ... Raabe. , The study involved 37 stroke patients ... of these, 16 patients or 43 percent, reported an improvement ...
... spread of HIV in the population. Some governments indifference ... education efforts, advocates said this week at the World ... ,"Violence is largely a cause of HIV ... in the streets, violence everywhere," Ludfine Anyango, the national ...
... epidemic that ravaged medieval Europe has a weakness that could ... to a study published on Thursday. ,A bacterium ... Black Death spread when people are bitten by an infected ... through coughing or sneezing. ,There are periodic natural ...
... When it comes to some of today’s health issues, ... risk factors related to certain diseases – concludes// a ... in their ability to reduce risk compared to their ... Kingdom who conducted the literature review. The researchers analyzed ...
... heavily on alternative therapists who mistreat their patients sexually ... therapists said to exist in Britain and there are ... On the other hand, completely qualified medical practitioners who ... rules and guidelines regarding their relationship with their patients. ...
... A new study shows that the Israeli men have a ... countries like Iceland, Japan, Switzerland, Sweden and Australia, where it ... ,According to a Taub Center for social policy ... of 78 years. Israeli women live longer than men, ...
Cached Medicine News:Health News:Violence Against Women Fueling Spread of HIV Worldwide 2Health News:Scientists Find Potential Weakness In Plague Germ 2Health News:Benefits of Fruit and Vegetable Juices 2
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Medicine Products: